Trials / Completed
CompletedNCT00336765
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Kadmon Corporation, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given orally daily to adults with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL647 | Tablets supplied in 50-mg strength administered orally daily |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2010-08-01
- Completion
- 2010-09-01
- First posted
- 2006-06-14
- Last updated
- 2022-05-13
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00336765. Inclusion in this directory is not an endorsement.